Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
7.18
-0.12 (-1.64%)
Apr 24, 2025, 10:19 AM CET
0.00%
Market Cap 145.70M
Revenue (ttm) 48.21M
Net Income (ttm) 14.86M
Shares Out 19.96M
EPS (ttm) 0.72
PE Ratio 10.11
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,783
Average Volume 96,313
Open 7.32
Previous Close 7.30
Day's Range 7.08 - 7.32
52-Week Range 5.20 - 11.20
Beta 0.67
RSI 50.04
Earnings Date Apr 1, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 22
Stock Exchange SIX Swiss Exchange
Ticker Symbol NWRN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

Newron Pharmaceuticals reports FY results

22 days ago - Seeking Alpha